Mingnan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mingnan Chen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Shuyun Dong
13 shared publicationsPeng Zhao
Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
9 shared publicationsPeng Wang
Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
5 shared publicationsYujia Zhai
5 shared publications- Shuyun Dong
Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84124, USA
4 shared publications Xiao He
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA
4 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in Cell Biomaterials
Immune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes
- 22 May 2026
- Published by Elsevier in Cell Biomaterials
Open AccessImmune context governs stage-specific responses to depleting anti-PD-1 antibody in type 1 diabetes
- Open Access
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1644903
PD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis
Background: Bispecific killer engagers (BiKEs), which harness natural killer cells to deplete target cells, have garnered success in ablating tumor cells but have not been well explored in eliminating primary cells, such as effector cells in autoimmune diseases. Previously, we reported a BiKE that targeted human lymphocytes expressing programmed death-1 (PD-1). The BiKE was shown to promote NK cell-mediated depletion of PD-1+ cells in vitro. Here, we posited that a mouse-specific PD-1 BiKE could be used as a tool to deplete PD-1+ cells in vivo.Methods: PD-1 BiKE was designed and produced in an IgG-like format. The BiKE was characterized for its functional binding, ability to facilitate NK cell-PD-1+ cell-cell interactions, and depletion of PD-1+ cells using several in vitro assays. The BiKE was then evaluated for its ability to deplete PD-1+ T cells in vivo using an EL4 tumor model, and the EAE model.Results: PD-1 BiKE demonstrated selective binding to PD-1+ T cells encompassing both a cell line (EL4) and primary cells. PD-1 BiKE simultaneously engaged its two targets, PD-1+ and NK cells, and mediated a 63% increase in cell-cell interactions between the two targets. In co-cultures of primary PD-1+ T cells and NK cells, the BiKE reduced the number of T cells by 28%. Importantly, PD-1 BiKE did not reduce PD-1- T cells when co-cultured with NK cells. In vivo, PD-1 BiKE reduced the fraction of inoculated EL4 cells by ~53%. In EAE mice, PD-1 BiKE reduced the average number of primary PD-1+ T cells by 56% and 65% in the spinal cords and brains, respectively. Beyond the IgG-like BiKE, two non-IgG-like BiKEs were also designed and generated and demonstrated strong but distinct binding to PD-1 and CD16.Conclusions: The IgG-like PD-1 BiKE bound to both cellular targets, CD16 and PD-1, and was able to deplete primary PD-1+ T lymphocytes in the EAE model. Altogether, the work showcases the effectiveness of using BiKEs to deplete non-malignant cells.
- 13 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1644903
Open AccessPD-1 Bispecific Killer Engager (PD-1 BiKE) effectively depletes effector T lymphocytes in experimental autoimmune encephalomyelitis
Background: Bispecific killer engagers (BiKEs), which harness natural killer cells to deplete target cells, have garnered success in ablating tumor cells but have not been well explored in eliminating primary cells, such as effector cells in autoimmune diseases. Previously, we reported a BiKE that targeted human lymphocytes expressing programmed death-1 (PD-1). The BiKE was shown to promote NK cell-mediated depletion of PD-1+ cells in vitro. Here, we posited that a mouse-specific PD-1 BiKE could be used as a tool to deplete PD-1+ cells in vivo.Methods: PD-1 BiKE was designed and produced in an IgG-like format. The BiKE was characterized for its functional binding, ability to facilitate NK cell-PD-1+ cell-cell interactions, and depletion of PD-1+ cells using several in vitro assays. The BiKE was then evaluated for its ability to deplete PD-1+ T cells in vivo using an EL4 tumor model, and the EAE model.Results: PD-1 BiKE demonstrated selective binding to PD-1+ T cells encompassing both a cell line (EL4) and primary cells. PD-1 BiKE simultaneously engaged its two targets, PD-1+ and NK cells, and mediated a 63% increase in cell-cell interactions between the two targets. In co-cultures of primary PD-1+ T cells and NK cells, the BiKE reduced the number of T cells by 28%. Importantly, PD-1 BiKE did not reduce PD-1- T cells when co-cultured with NK cells. In vivo, PD-1 BiKE reduced the fraction of inoculated EL4 cells by ~53%. In EAE mice, PD-1 BiKE reduced the average number of primary PD-1+ T cells by 56% and 65% in the spinal cords and brains, respectively. Beyond the IgG-like BiKE, two non-IgG-like BiKEs were also designed and generated and demonstrated strong but distinct binding to PD-1 and CD16.Conclusions: The IgG-like PD-1 BiKE bound to both cellular targets, CD16 and PD-1, and was able to deplete primary PD-1+ T lymphocytes in the EAE model. Altogether, the work showcases the effectiveness of using BiKEs to deplete non-malignant cells.
- Open Access
- 4 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1230-1241
Bispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
- 4 November 2024
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (3) , 1230-1241
Open AccessBispecific killer engager for targeted depletion of PD-1 positive lymphocytes: A new avenue for autoimmune disease treatment
- 22 August 2023
- Published by Wiley in Protein Science
- Vol. 32 (9) , e4741
Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Programmed death‐1 (PD‐1), an immune checkpoint receptor, is expressed on activated lymphocytes, macrophages, and some types of tumor cells. While PD‐1+ cells have been implicated in outcomes of cancer immunity, autoimmunity, and chronic infections, the exact roles of these cells in various physiological and pathological processes remain elusive. Molecules that target and deplete PD‐1+ cells would be instrumental in defining the roles unambiguously. Previously, an immunotoxin has been generated for the depletion of PD‐1+ cells though its usage is impeded by its low production yield. Thus, a more practical molecular tool is desired to deplete PD‐1+ cells and to examine functions of these cells. We designed and generated a novel anti‐PD1 diphtheria immunotoxin, termed PD‐1 DIT, targeting PD‐1+ cells. PD‐1 DIT is comprised of two single chain variable fragments (scFv) derived from an anti‐PD‐1 antibody, coupled with the catalytic and translocation domains of the diphtheria toxin. PD‐1 DIT was produced using a yeast expression system that has been engineered to efficiently produce protein toxins. The yield of PD‐1 DIT reached 1–2 mg/L culture, which is 10 times higher than the previously reported immunotoxin. Flow cytometry and confocal microscopy analyses confirmed that PD‐1 DIT specifically binds to and enters PD‐1+ cells. The binding avidities between PD‐1 DIT and two PD‐1+ cell lines are approximately 25 nM. Moreover, PD‐1 DIT demonstrated potent cytotoxicity toward PD‐1+ cells, with a half maximal effective concentration (EC50) value of 1 nM. In vivo experiments further showed that PD‐1 DIT effectively depleted PD‐1+ cells and enabled mice inoculated with PD‐1+ tumor cells to survive throughout the study. Our findings using PD‐1 DIT revealed the critical role of pancreatic PD‐1+ T cells in the development of type‐1 diabetes (T1D). Additionally, we observed that PD‐1 DIT treatment ameliorated relapsing–remitting experimental autoimmune encephalomyelitis (RR‐EAE), a mouse model of relapsing–remitting multiple sclerosis (RR‐MS). Lastly, we did not observe significant hepatotoxicity in mice treated with PD‐1 DIT, which had been reported for other immunotoxins derived from the diphtheria toxin. With its remarkable selective and potent cytotoxicity toward PD‐1+ cells, coupled with its high production yield, PD‐1 DIT emerges as a powerful biotechnological tool for elucidating the physiological roles of PD‐1+ cells. Furthermore, the potential of PD‐1 DIT to be developed into a novel therapeutic agent becomes evident.
- 22 August 2023
- Published by Wiley in Protein Science
- Vol. 32 (9) , e4741
Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Programmed death‐1 (PD‐1), an immune checkpoint receptor, is expressed on activated lymphocytes, macrophages, and some types of tumor cells. While PD‐1+ cells have been implicated in outcomes of cancer immunity, autoimmunity, and chronic infections, the exact roles of these cells in various physiological and pathological processes remain elusive. Molecules that target and deplete PD‐1+ cells would be instrumental in defining the roles unambiguously. Previously, an immunotoxin has been generated for the depletion of PD‐1+ cells though its usage is impeded by its low production yield. Thus, a more practical molecular tool is desired to deplete PD‐1+ cells and to examine functions of these cells. We designed and generated a novel anti‐PD1 diphtheria immunotoxin, termed PD‐1 DIT, targeting PD‐1+ cells. PD‐1 DIT is comprised of two single chain variable fragments (scFv) derived from an anti‐PD‐1 antibody, coupled with the catalytic and translocation domains of the diphtheria toxin. PD‐1 DIT was produced using a yeast expression system that has been engineered to efficiently produce protein toxins. The yield of PD‐1 DIT reached 1–2 mg/L culture, which is 10 times higher than the previously reported immunotoxin. Flow cytometry and confocal microscopy analyses confirmed that PD‐1 DIT specifically binds to and enters PD‐1+ cells. The binding avidities between PD‐1 DIT and two PD‐1+ cell lines are approximately 25 nM. Moreover, PD‐1 DIT demonstrated potent cytotoxicity toward PD‐1+ cells, with a half maximal effective concentration (EC50) value of 1 nM. In vivo experiments further showed that PD‐1 DIT effectively depleted PD‐1+ cells and enabled mice inoculated with PD‐1+ tumor cells to survive throughout the study. Our findings using PD‐1 DIT revealed the critical role of pancreatic PD‐1+ T cells in the development of type‐1 diabetes (T1D). Additionally, we observed that PD‐1 DIT treatment ameliorated relapsing–remitting experimental autoimmune encephalomyelitis (RR‐EAE), a mouse model of relapsing–remitting multiple sclerosis (RR‐MS). Lastly, we did not observe significant hepatotoxicity in mice treated with PD‐1 DIT, which had been reported for other immunotoxins derived from the diphtheria toxin. With its remarkable selective and potent cytotoxicity toward PD‐1+ cells, coupled with its high production yield, PD‐1 DIT emerges as a powerful biotechnological tool for elucidating the physiological roles of PD‐1+ cells. Furthermore, the potential of PD‐1 DIT to be developed into a novel therapeutic agent becomes evident.
- Open Access
- 15 July 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 349, 425-433
Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
- 15 July 2022
- Published by Elsevier in Journal of Controlled Release
- Vol. 349, 425-433
Open AccessAntibody-mediated depletion of programmed death 1-positive (PD-1+) cells
- Open Access
- 21 April 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Autoimmune diseases, such as multiple sclerosis and type-1 diabetes, are the outcomes of a failure of immune tolerance. Immune tolerance is sustained through interplays between two inter-dependent clusters of immune activities: immune stimulation and immune regulation. The mechanisms of immune regulation are exploited as therapeutic targets for the treatment of autoimmune diseases. One of these mechanisms is immune checkpoints (ICPs). The roles of ICPs in maintaining immune tolerance and hence suppressing autoimmunity were revealed in animal models and validated by the clinical successes of ICP-targeted therapeutics for autoimmune diseases. Recently, these roles were highlighted by the clinical discovery that the blockade of ICPs causes autoimmune disorders. Given the crucial roles of ICPs in immune tolerance, it is plausible to leverage ICPs as a group of therapeutic targets to restore immune tolerance and treat autoimmune diseases. In this review, we first summarize working mechanisms of ICPs, particularly those that have been utilized for therapeutic development. Then, we recount the agents and approaches that were developed to target ICPs and treat autoimmune disorders. These agents take forms of fusion proteins, antibodies, nucleic acids, and cells. We also review and discuss safety information for these therapeutics. We wrap up this review by providing prospects for the development of ICP-targeting therapeutics. In summary, the ever-increasing studies and results of ICP-targeting of therapeutics underscore their tremendous potential to become a powerful class of medicine for autoimmune diseases.
- 21 April 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessImmune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases
Autoimmune diseases, such as multiple sclerosis and type-1 diabetes, are the outcomes of a failure of immune tolerance. Immune tolerance is sustained through interplays between two inter-dependent clusters of immune activities: immune stimulation and immune regulation. The mechanisms of immune regulation are exploited as therapeutic targets for the treatment of autoimmune diseases. One of these mechanisms is immune checkpoints (ICPs). The roles of ICPs in maintaining immune tolerance and hence suppressing autoimmunity were revealed in animal models and validated by the clinical successes of ICP-targeted therapeutics for autoimmune diseases. Recently, these roles were highlighted by the clinical discovery that the blockade of ICPs causes autoimmune disorders. Given the crucial roles of ICPs in immune tolerance, it is plausible to leverage ICPs as a group of therapeutic targets to restore immune tolerance and treat autoimmune diseases. In this review, we first summarize working mechanisms of ICPs, particularly those that have been utilized for therapeutic development. Then, we recount the agents and approaches that were developed to target ICPs and treat autoimmune disorders. These agents take forms of fusion proteins, antibodies, nucleic acids, and cells. We also review and discuss safety information for these therapeutics. We wrap up this review by providing prospects for the development of ICP-targeting therapeutics. In summary, the ever-increasing studies and results of ICP-targeting of therapeutics underscore their tremendous potential to become a powerful class of medicine for autoimmune diseases.
- 19 September 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 328, 653-664
Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity
- 19 September 2020
- Published by Elsevier in Journal of Controlled Release
- Vol. 328, 653-664
Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity
- Open Access
- 1 January 2020
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (16) , 7403-7405
Critical reviews of immunotheranostics
Immunity is the most critical and well-regulated protection to the body. Immunity is implicated in a wide range of diseases and serves as the foundation for immunotherapy. Immunotheranostics is the idea of improving immunotherapy through the organic integration of therapeutic, diagnostic, and screening technologies. This special issue collects reviews and opinions from prominent contributors in the immunotheranostic field who represent highly diversified research expertise. The immunotherapeutics discussed in this issue range from small molecules, peptides, antibodies, nanoparticles, and to cells. Discussions from the therapeutic development perspective are accompanied by opinions from the biology and medicine aspects. Further, there are reviews about different types of imaging technologies and their applications in immunotherapy. Lastly, one review raises attention to mass spectrometry for its utilization in the diagnosis and assessment for immunotherapy. In summary, this special issue is a showcase for what is happening in immunotheranostics. Moreover, it is also a justified wish list for what should and will happen in immunotheranostics.
- 1 January 2020
- Published by Ivyspring International Publisher in Theranostics
- Vol. 10 (16) , 7403-7405
Open AccessCritical reviews of immunotheranostics
Immunity is the most critical and well-regulated protection to the body. Immunity is implicated in a wide range of diseases and serves as the foundation for immunotherapy. Immunotheranostics is the idea of improving immunotherapy through the organic integration of therapeutic, diagnostic, and screening technologies. This special issue collects reviews and opinions from prominent contributors in the immunotheranostic field who represent highly diversified research expertise. The immunotherapeutics discussed in this issue range from small molecules, peptides, antibodies, nanoparticles, and to cells. Discussions from the therapeutic development perspective are accompanied by opinions from the biology and medicine aspects. Further, there are reviews about different types of imaging technologies and their applications in immunotherapy. Lastly, one review raises attention to mass spectrometry for its utilization in the diagnosis and assessment for immunotherapy. In summary, this special issue is a showcase for what is happening in immunotheranostics. Moreover, it is also a justified wish list for what should and will happen in immunotheranostics.
- 4 March 2019
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 3 (4) , 292-305
Depletion of PD-1-positive cells ameliorates autoimmune disease
Targeted suppression of autoimmune diseases without collateral suppression of normal immunity remains an elusive yet clinically important goal. Targeted blockade of programmed-cell-death-protein-1 (PD-1)—an immune checkpoint factor expressed by activated T cells and B cells—is an efficacious therapy for potentiating immune activation against tumours. Here we show that an immunotoxin consisting of an anti-PD-1 single-chain variable fragment, an albumin-binding domain and Pseudomonas exotoxin targeting PD-1-expressing cells, selectively recognizes and induces the killing of the cells. Administration of the immunotoxin to mouse models of autoimmune diabetes delays disease onset, and its administration in mice paralysed by experimental autoimmune encephalomyelitis ameliorates symptoms. In all mouse models, the immunotoxin reduced the numbers of PD-1-expressing cells, of total T cells and of cells of an autoreactive T-cell clone found in inflamed organs, while maintaining active adaptive immunity, as evidenced by full-strength immune responses to vaccinations. The targeted depletion of PD-1-expressing cells contingent to the preservation of adaptive immunity might be effective in the treatment of a wide range of autoimmune diseases.
- 4 March 2019
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 3 (4) , 292-305
Depletion of PD-1-positive cells ameliorates autoimmune disease
Targeted suppression of autoimmune diseases without collateral suppression of normal immunity remains an elusive yet clinically important goal. Targeted blockade of programmed-cell-death-protein-1 (PD-1)—an immune checkpoint factor expressed by activated T cells and B cells—is an efficacious therapy for potentiating immune activation against tumours. Here we show that an immunotoxin consisting of an anti-PD-1 single-chain variable fragment, an albumin-binding domain and Pseudomonas exotoxin targeting PD-1-expressing cells, selectively recognizes and induces the killing of the cells. Administration of the immunotoxin to mouse models of autoimmune diabetes delays disease onset, and its administration in mice paralysed by experimental autoimmune encephalomyelitis ameliorates symptoms. In all mouse models, the immunotoxin reduced the numbers of PD-1-expressing cells, of total T cells and of cells of an autoreactive T-cell clone found in inflamed organs, while maintaining active adaptive immunity, as evidenced by full-strength immune responses to vaccinations. The targeted depletion of PD-1-expressing cells contingent to the preservation of adaptive immunity might be effective in the treatment of a wide range of autoimmune diseases.
- 1 November 2018
- Published by Elsevier in Biomaterials
- Vol. 182, 92-103
Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo
- 1 November 2018
- Published by Elsevier in Biomaterials
- Vol. 182, 92-103
Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo